RGLS Regulus Therapeutics Inc.

1.31
-0.01  -1%
Previous Close 1.32
Open 1.33
Price To book 6.90
Market Cap 135959306
Shares 103,785,730
Volume 231,341
Short Ratio 5.17
Av. Daily Volume 858,614

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due year end 2017.
RG-012
Renal biopsy study in Alport patients
Phase 2 interim data due mid-2018.
RG-012 - HERA
Alport Syndrome
Clinical hold placed June 2016. Noted June 12, 2017 that it plans to discontinue program.
RG-101
Hepatitis C virus (HCV)

Latest News

  1. Regulus to Present at the 2017 Wells Fargo Healthcare Conference
  2. Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?
  3. Edited Transcript of RGLS earnings conference call or presentation 1-Aug-17 9:00pm GMT
  4. Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference
  5. Regulus reports 2Q loss
  6. Regulus Reports Second Quarter 2017 Financial Results and Recent Events
  7. Investor Network: Regulus Therapeutics Inc. to Host Earnings Call
  8. Regulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares
  9. Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
  10. Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017
  11. Regulus Announces Pricing of Public Offering of Common Stock
  12. Regulus Announces Commencement of Public Offering of Common Stock
  13. Chardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program Discontinuations
  14. Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip
  15. Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer
  16. Regulus Announces Pipeline Updates and Advancements
  17. Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics
  18. Pascale Witz Joins Regulus Board of Directors
  19. Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT
  20. Q1 Losses Couldn't Drag Regulus or Corvus Pharmaceuticals Down